Search - tctmd.com

Displaying 1 - 20 of 97

Sort: Relevancy | Date

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

News Conference News AHA 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Michael O'Riordan

November 11, 2025

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats

News Conference News TCT 2025

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats

October 28, 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

News Conference News ESC 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

September 05, 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

March 30, 2025

Transplant Recipients on Medicaid More Likely to Develop Allograft Vasculopathy

News Conference News STS 2025

Transplant Recipients on Medicaid More Likely to Develop Allograft Vasculopathy

Yael L. Maxwell

January 30, 2025

STS Experts Tackle Need For Women-Only Trials in Surgery

News Conference News STS 2025

STS Experts Tackle Need For Women-Only Trials in Surgery

Yael L. Maxwell

January 29, 2025

Amid Declining Use, Mechanical SAVR Valves Beat Bioprosthetic for Survival

News Conference News STS 2025

Amid Declining Use, Mechanical SAVR Valves Beat Bioprosthetic for Survival

Yael L. Maxwell

January 27, 2025

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes

News Conference News AHA 2024

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes

Michael O'Riordan

November 17, 2024

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

News Conference News AHA 2024

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

Yael L. Maxwell

November 17, 2024

At EACTS 2024, Surgeons and Cardiologists Move Past EXCEL Firestorm

News Conference News EACTS 2024

At EACTS 2024, Surgeons and Cardiologists Move Past EXCEL Firestorm

Yael L. Maxwell

October 22, 2024

‘Teleprehabilitation’ Before Cardiac Surgery Improves the Outcomes That Follow

News Conference News EACTS 2024

‘Teleprehabilitation’ Before Cardiac Surgery Improves the Outcomes That Follow

Yael L. Maxwell

October 17, 2024

Enhanced Recovery After Cardiac Surgery: Fewer Complications, Shorter Stays

News Conference News EACTS 2024

Enhanced Recovery After Cardiac Surgery: Fewer Complications, Shorter Stays

Yael L. Maxwell

October 16, 2024

MACE in CV Trials: Has the Outcome Outlived Its Role?

News Conference News EACTS 2024

MACE in CV Trials: Has the Outcome Outlived Its Role?

Yael L. Maxwell

October 11, 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

News Conference News ESC 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Michael O'Riordan

September 17, 2024

Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

News Conference News EuroPCR 2024

NOW PUBLISHED - Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

Michael O'Riordan

May 14, 2024

Concomitant AF Procedures During Non-Mitral Surgery Less Likely in Women

News Conference News

Concomitant AF Procedures During Non-Mitral Surgery Less Likely in Women

Yael L. Maxwell

May 09, 2024

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

News Conference News TCT 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Michael O'Riordan

November 01, 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.